GlassScriptPhysician profile
Swati Sikaria
NPI 1497048060
$9,514.09
in general payments reported to CMS, 2019-2025
30 companies · $598 in 2025
The $598 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $864 · 2020: $614 · 2021: $4,556 · 2022: $1,721 · 2023: $537 · 2024: $625 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,697 · Education: $62.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,697.49 |
| Education | $62.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $6,268.41 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,531.28 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $505.02 | 2022-2025 | Calquence |
| Genentech USA, INC. | $198.73 | 2023-2025 | Tecentriq, Venclexta, Polivy |
| Array Biopharma INC | $161.00 | 2024-2025 | Braftovi, Tukysa, Mektovi |
| Pfizer INC. | $103.31 | 2023-2024 | |
| Glaxosmithkline, LLC. | $102.79 | 2023-2024 | Zejula, Jemperli |
| Merck Sharp & Dohme LLC | $59.64 | 2024-2025 | Keytruda |
| Janssen Biotech, INC. | $49.87 | 2025 | Erleada, Balversa, Akeega |
| Sirtex Medical INC | $43.07 | 2023 | Sir-Spheres Microspheres |
| Mirati Therapeutics, INC. | $42.00 | 2023 | Krazati |
| Stemline Therapeutics INC. | $40.84 | 2024-2025 | Orserdu |
| Celgene Corporation | $40.22 | 2023-2025 | Reblozyl |
| Genzyme Corporation | $35.48 | 2024 | |
| Ge Healthcare | $30.85 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $30.77 | 2025 | Vowst |
| Springworks Therapeutics, INC. | $28.57 | 2024 | Ogsiveo |
| Dendreon Pharmaceuticals LLC | $27.95 | 2025 | Provenge |
| Daiichi Sankyo INC. | $27.77 | 2023 | Enhertu |
| Kite Pharma, INC. | $27.13 | 2024 | Yescarta |
| Iovance Biotherapeutics, INC. | $26.12 | 2025 | Amtagvi |
| Agios Pharmaceuticals, INC. | $25.00 | 2024 | Pyrukynd |
| Takeda Pharmaceuticals U.S.A., INC. | $23.62 | 2023 | Fruzaqla |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| Mylan Institutional INC. | $19.66 | 2023 | Fulphila, Ogivri |
| Amgen INC. | $18.39 | 2023 | Lumakras |
| Puma Biotechnology, INC. | $15.10 | 2025 | |
| Epizyme, INC. | $11.50 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swati Sikaria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.